PDYPY - Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2025 Update
2025-05-26 21:54:19 ET
Summary
- Duquesne Family Office’s Q1 2025 13F shows a portfolio value drop to $3.06B, with high concentration in top holdings like Natera and Teva Pharma.
- Significant new positions include DocuSign, CCC Intelligent Solutions, EQT, and Caesars Entertainment.
- Major stake increases were made in Teva Pharma, Insmed, Taiwan Semi, Eli Lilly, and YPF, while Natera, Woodward, and Philip Morris saw notable trims.
- Several positions were fully exited, including Sketchers, SLM, Warner Brothers Discovery, and Vistra, highlighting active portfolio management amid market shifts.
This article is part of a series that provides an ongoing analysis of the changes made to Duquesne Family Office’s 13F stock portfolio on a quarterly basis. It is based on Stanley Druckenmiller’s regulatory 13F Form filed on 05/15/2025. The 13F portfolio value decreased from $3.72B to $3.06B this quarter. The holdings are concentrated with recent 13F reports showing around 75 positions, many of which are very small. There are 39 securities that are significantly large (more than ~0.5% of the portfolio each) and they are the focus of this article. The largest five stakes are Natera, Teva Pharma, Coupang, Woodward, and Philip Morris. They add up to ~41% of the portfolio. Please visit our Tracking Stanley Druckenmiller’s Duquesne Portfolio series to get an idea of their investment philosophy and our previous update for the fund’s moves during Q4 2024....
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2025 Update